Lori Nembirkow
General Counsel bei CENTRIC BRANDS INC.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jason Rabin | M | 54 | 6 Jahre | |
| Anurup S. Pruthi | M | 56 | 6 Jahre | |
| Marc Schneider | M | 64 | 4 Jahre | |
| Roger Czuchra | M | 54 | 5 Jahre | |
| Jake Brandman | M | - | 8 Jahre | |
| Sid Keswani | M | - | 3 Jahre | |
| Tom Nevell | M | - | 8 Jahre | |
| Joe Favuzza | M | - | 6 Jahre | |
| Karen Coe | F | - | 6 Jahre | |
| Joseph J. Sciametta | M | - | 4 Jahre | |
| Ruth Hartman | F | - | 3 Jahre | |
| Tami Fersko | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Andrew Tarshis | M | 58 | 4 Jahre | |
| Hamish S. Sandhu | M | 61 | 10 Jahre | |
| Timothy J. Creech | M | 63 |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 Jahre |
| Marc Crossman | M | 53 | 16 Jahre | |
| Samuel J. Furrow | M | 82 | 18 Jahre | |
| Matthew Eby | M | 52 | 4 Jahre | |
| Randall Kessler | M | 43 | 2 Jahre | |
| Thomas F. O'Riordan | M | 68 | 7 Jahre | |
| Robert Taylor Petrini | M | 49 | 2 Jahre | |
| M. Ross Johnson | M | 79 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 4 Jahre |
| Joseph M. Dahan | M | 56 | 8 Jahre | |
| Michael F. Buckley | M | 60 | 2 Jahre | |
| Robert Ross | M | 55 | 1 Jahre | |
| William Sweedler | M | 57 | 4 Jahre | |
| Joanne Calabrese | F | 65 | 4 Jahre | |
| Kelly Hoffman | M | 66 | 14 Jahre | |
| Suhail Rizvi | M | 58 | 13 Jahre | |
| Glenn Krevlin | M | 64 | 2 Jahre | |
| Kent A. Savage | M | 62 | 17 Jahre | |
| Walter McLallen | M | 58 | 4 Jahre | |
| Sarah Choufani | F | - | - | |
| Myung-Cheol Kang | M | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 8 Jahre |
| Diego Miralles | M | 62 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 5 Jahre |
| Samuel Hopkins | M | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 6 Jahre |
| Peter Kim | M | 53 | 2 Jahre | |
| Pamela Gill Alabaster | F | - | - | |
| Sherman Edmiston | M | 61 | - | |
| Samuel Joseph Furrow | M | 50 | - | |
| Michael Alrutz | M | 54 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 9 Jahre |
| Walter Capone | M | 59 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 5 Jahre |
| Patrick Bartels | M | 49 | - | |
| Marc Saffer | M | 66 | 1 Jahre | |
| Marjorie Bowen | F | 58 | - | |
| Kevin Tang | M | 57 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 Jahre |
| E. Gary Cook | M | 79 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 Jahre |
| Steven Skolsky | M | 68 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 2 Jahre |
| Richard Allan Quiroga | M | 64 | 2 Jahre | |
| Julian Baker | M | 57 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 Jahre |
| Felix Baker | M | 55 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 Jahre |
| Laura Ritchey | F | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 52 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Lori Nembirkow
- Persönliches Netzwerk
